Oakwood Medical Investors

Raul D. Recarey, the firm's founder, serves as the central investment decision-maker. Recarey brings an operating background in medical device commercialization, which shapes the firm's clinical-first due-diligence process. Oakwood's lean partnership structure means Recarey personally leads or co-leads the majority of the firm's transactions rather than delegating to a large investment committee.

Oakwood sources opportunities through Recarey's relationships with academic medical centers, surgeon-inventors, and regulatory consultants. The firm's St. Louis location provides proximity to Midwestern research institutions in the orthopedic and cardiovascular space, while its narrow sub-sector focus — electrophysiology, spine, wound care — means referrals come from a tight network of clinicians who recognize Oakwood's technical fluency.

Oakwood operates as a direct investor, taking lead or co-lead equity positions in portfolio companies rather than committing to external venture funds. There is no public record of the firm acting as a limited partner in other managers' vehicles. Its model relies on board-level engagement and hands-on regulatory support.

The firm invests from Seed through Series B stages, typically entering when companies are preparing for pivotal clinical trials or initial FDA submissions. Oakwood's capital goes to work at the point where clinical risk — not commercial risk — defines the valuation, and it frequently remains active through subsequent financing rounds.

Oakwood concentrates on medical devices, diagnostics, and digital health. The firm does not have a public track record in biopharmaceuticals, drug discovery platforms, or later-stage healthcare services roll-ups. Its avoidance of small-molecule therapeutics distinguishes it from generalist life-science VC firms and reflects Recarey's device-industry operating roots.